Purchase this article with an account.
R. P. Kowalski, E. G. Romanowski, F. S. Mah, R. M. Q. Shanks, E. C. Si, L. M. Bowman, K. Hosseini, Y. J. Gordon; Evaluation of Azithromycin Topical Ophthalmic Formulations Using Time-Kill Studies. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2666.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We compared the antibacterial efficacy of AzaSite (1.0% azithromycin formulated in DuraSite containing 0.01% benzalkonium chloride) to Azyter (1.5% azithromycin formulated in a non-preserved oil) using in vitro time-kill studies..
Time-kill studies were processed to test Proteus mirabilis, Staphylococcus epidermidis, S aureus, S aureus [MRSA] azithromycin-resistant, Streptocoocus viridans, St pneumoniae, Pseudomonas aeruginosa, P putida, Branhamella catarrhalis, Bacillus cereus, Enterococcus faecalis, Serratia marcescens, Enterobacter aerogenes, Klebsiella pneumoniae, E coli, and Haemophilus influenzae to AzaSite and Azyter at time points 0, 15 min, 30 min, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs, and 24 hrs, using the standard colony count method.
AzaSite (94%, 15/16) significantly (p=0.00017, Fisher’s exact test) killed more bacterial isolates by 15 min than Azyter (25%, 4/16). The colony counts for Proteus mirabilis at each time point (15 min to 8 hrs) were more reduced for AzaSite than Azyter.
In vitro time-kill studies demonstrated that AzaSite was more effective in eradicating bacterial isolates than Azyter. Clinical trials are recommended to determine if these in vitro results parallel in vivo efficacy.
This PDF is available to Subscribers Only